Biomedical HIV Prevention Trials: Results, milestones and more

**JANUARY 2019**
- Vaginal ring
- Oral PrEP [Daily pill]
- Long-acting injectable
- Antibody
- Preventive HIV vaccine

**JANUARY 2020**
- F/TAF (DISCOVER–MSM/TG WOMEN) [Monthly pill]
- Cabotegravir (HPTN 083)
- Cabotegravir (HPTN 084)
- VRC01 (HVTN 704/HPTN 085)
- VRC01 (HVTN 703/HPTN 081)
- ALVAC (HVTN 702/Uhambo) Immunizations halted for non-efficacy
- May 2020: Blinded, randomized portion of the trial stopped early for efficacy. Participants in both arms of the study will be offered CAB LA
- FDA approval for adults and adolescents who don’t have receptive vaginal sex.
- MK-8591/Islatravir (NCT04003103)*
- Research planned to gather data needed for people excluded from the current FDA indication.
- February 2020: Trial stopped early for non-efficacy.

**JANUARY 2021**
- European Medicines Agency issues a positive opinion
- FDA approval
- FDA approval for adults and adolescents who don’t have receptive vaginal sex.
- Submission to the US Food and Drug Administration (FDA)
- Submission to the South African Health Products Regulatory Authority (SAHPRA)
- Planned
- Ongoing
- PrEP and vaccine

**JANUARY 2022**
- DNA-MVA-env or DNA-env with F/TAF or F/TDF (PrEPVacc)

*Phase IIa trial*